Sarepta Therapeutics, Inc. (SRPT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases.
Is Sarepta Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of November 4, 2026, Sarepta Therapeutics, Inc. (SRPT) trades at $18.99 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Sarepta Therapeutics, Inc.
Market cap $2B · 52 weeks $15 – $24 (21% below the high) · P/E no earnings · 2027 est. P/E 55.1× · Dividend none · Next earnings November 5, 2026 · expected EPS $0.07 · Closing price, Nov 4 · accounts published Aug 5.
- Valuation: P/Sales 1.1× (no earnings).
- Balance sheet: Altman Z −0.9 (fragile).
- Earnings: 4 of 8 (uneven).
Where would it trade at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 3 of 4 pass
- Total Debt 1.1×, borderline.
- Cash Runway 55 months, passes.
- R&D / Market cap 76.5%, passes.
- Market cap / Cash 2.1×, passes.
- Annual cash burn $1.96, info.
Against its peers (reference peers) — Sarepta Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -5.3%; $2.0B. PTC Therapeutics, Inc. (P/E —; EV/EBITDA 29.9×; ROIC 5.7%; $5.8B), Alnylam Pharmaceuticals, Inc. (P/E 8.1×; EV/EBITDA 16.6×; ROIC 15.4%; $21.6B), Harmony Biosciences Holdings, Inc. (P/E 11.4×; EV/EBITDA 5.1×; ROIC 13.7%; $2.0B).
Profitability
| Return on Equity | -9.96% |
| Return on Invested Capital | -5.33% |
| Return on Assets | -4.29% |
| Gross Margin | 58.56% |
| Operating Margin | -7.26% |
| Net Margin | -6.93% |
Financial Health
| Debt / Equity | 0.68 |
| Current Ratio | 4.42 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -0.90 |
Price Performance
| 1 month | +11.09% |
| 3 months | +14.60% |
| Year-to-date | -10.64% |
| 1 year | +3.00% |
| 3 years | -75.99% |
| 5 years | -78.38% |
| 10 years | -50.51% |
Related companies: ALNY · IONS · PTCT · DYN
Explore sector: Healthcare · Biotechnology
More sections of SRPT: Financials · Valuation · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks